PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
EBIT growth of 10.76% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
10.76%
Operating income growth of 10.76% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
11.35%
Net income growth of 11.35% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
31.03%
EPS growth of 31.03% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
31.72%
Diluted EPS growth of 31.72% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
29.31%
Share change of 29.31% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
29.44%
Diluted share change of 29.44% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth of 2.31% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
3.06%
FCF growth of 3.06% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
64.50%
OCF/share CAGR of 64.50% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
73.57%
3Y OCF/share growth of 73.57% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-9976.84%
Negative 10Y net income/share CAGR vs. Healthcare median of 4.55%. Seth Klarman might see a fundamental problem if peers maintain growth.
-124.34%
Negative 5Y CAGR while Healthcare median is 2.90%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
76.73%
3Y net income/share CAGR > 1.5x Healthcare median of 7.00%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
1493.31%
Equity/share CAGR of 1493.31% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-38.28%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-74.77%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth of 78.33% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
127.26%
BV/share growth of 127.26% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-9.95%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-7.53%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-21.01%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.